| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects PA McSweeney, D Niederwieser, JA Shizuru, BM Sandmaier, AJ Molina, ... Blood, The Journal of the American Society of Hematology 97 (11), 3390-3400, 2001 | 1661 | 2001 |
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ... J Clin Oncol 30 (36), 4541-4549, 2012 | 921 | 2012 |
| Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting … D Niederwieser, M Maris, JA Shizuru, E Petersdorf, U Hegenbart, ... Blood, The Journal of the American Society of Hematology 101 (4), 1620-1629, 2003 | 529 | 2003 |
| A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 121 (17), 3420-3427, 2013 | 494 | 2013 |
| Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma DG Maloney, AJ Molina, F Sahebi, KE Stockerl-Goldstein, BM Sandmaier, ... Blood 102 (9), 3447-3454, 2003 | 490 | 2003 |
| A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis G Palladini, U Hegenbart, P Milani, C Kimmich, A Foli, AD Ho, MV Rosin, ... Blood, The Journal of the American Society of Hematology 124 (15), 2325-2332, 2014 | 451 | 2014 |
| HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies MB Maris, D Niederwieser, BM Sandmaier, B Storer, M Stuart, D Maloney, ... Blood 102 (6), 2021-2030, 2003 | 399 | 2003 |
| Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study … P Dreger, H Döhner, M Ritgen, S Böttcher, R Busch, S Dietrich, D Bunjes, ... Blood, The Journal of the American Society of Hematology 116 (14), 2438-2447, 2010 | 397 | 2010 |
| Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors U Hegenbart, D Niederwieser, BM Sandmaier, MB Maris, JA Shizuru, ... Journal of Clinical Oncology 24 (3), 444-453, 2006 | 336 | 2006 |
| Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers SJ Buss, M Emami, D Mereles, G Korosoglou, AV Kristen, A Voss, ... Journal of the American College of Cardiology 60 (12), 1067-1076, 2012 | 313 | 2012 |
| Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete … M Bornhäuser, J Kienast, R Trenschel, A Burchert, U Hegenbart, ... The lancet oncology 13 (10), 1035-1044, 2012 | 296 | 2012 |
| Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death AV Kristen, TJ Dengler, U Hegenbart, SO Schonland, H Goldschmidt, ... Heart rhythm 5 (2), 235-240, 2008 | 271 | 2008 |
| Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia ML Sorror, MB Maris, BM Sandmaier, BE Storer, MJ Stuart, U Hegenbart, ... Journal of Clinical Oncology 23 (16), 3819-3829, 2005 | 266 | 2005 |
| Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients SO Schönland, U Hegenbart, T Bochtler, A Mangatter, M Hansberg, ... Blood, The Journal of the American Society of Hematology 119 (2), 488-493, 2012 | 256 | 2012 |
| Translocation t (11; 14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens T Bochtler, U Hegenbart, C Kunz, M Granzow, A Benner, A Seckinger, ... J Clin Oncol 33 (12), 1371-1378, 2015 | 223 | 2015 |
| Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system T Luft, S Dietrich, C Falk, M Conzelmann, M Hess, A Benner, F Neumann, ... Blood, The Journal of the American Society of Hematology 118 (6), 1685-1692, 2011 | 223 | 2011 |
| Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study G Gahrton, S Iacobelli, B Björkstrand, U Hegenbart, A Gruber, H Greinix, ... Blood, The Journal of the American Society of Hematology 121 (25), 5055-5063, 2013 | 216 | 2013 |
| Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study DE Reece, U Hegenbart, V Sanchorawala, G Merlini, G Palladini, J Bladé, ... Blood, The Journal of the American Society of Hematology 118 (4), 865-873, 2011 | 215 | 2011 |
| Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up B Björkstrand, S Iacobelli, U Hegenbart, A Gruber, H Greinix, L Volin, ... Journal of Clinical Oncology 29 (22), 3016-3022, 2011 | 214 | 2011 |
| Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study DE Reece, V Sanchorawala, U Hegenbart, G Merlini, G Palladini, ... Blood, The Journal of the American Society of Hematology 114 (8), 1489-1497, 2009 | 186 | 2009 |
